The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies
ConclusionResults suggest that once-monthly 150 mg oral ibandronate may be as effective as other oral bisphosphonates in reducing the risk of nonvertebral fractures. However, uncertainty associated to the small number of included studies, which are characterized by heterogeneous demographics and methodologies, precluded definitive conclusions.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Actonel | Databases & Libraries | Drugs & Pharmacology | Orthopaedics | Osteoporosis | Risedronate | Study | Women